New GLP-1 Drugs Coming in 2026: Orforglipron, CagriSema, and What Men Should Watch For

Updated March 2026 • 11 min read • Pipeline analysis

The 2026 Obesity Drug Landscape

Three years ago, the entire conversation around obesity medication centered on a single drug: semaglutide. In 2024, tirzepatide expanded the conversation to dual agonism. Now in 2026, the pipeline is a full-blown arms race between Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Amgen, and others — each chasing more weight loss, fewer side effects, and more convenient dosing.

For men, this matters more than the general population might realize. Several pipeline compounds are showing specific benefits in areas men care about: better muscle preservation, improved cardiovascular outcomes, liver fat reduction (NAFLD affects an estimated 30% of men globally), and mechanisms that may more favorably impact testosterone and body composition.

Here's what's coming, ranked by how close to market each drug is and how relevant it is for men.

Orforglipron — The Oral GLP-1 That Changes Everything

Orforglipron is the drug most likely to reach men's hands soonest, and it solves the single biggest barrier to GLP-1 adoption among men: injection aversion. Survey data consistently shows that 30–40% of men eligible for GLP-1 therapy never start because they don't want to self-inject. That's millions of men leaving effective treatment on the table.

Unlike oral semaglutide (Rybelsus), which is a peptide that requires strict fasting, no concurrent medications, and 30 minutes of sitting upright to absorb properly, orforglipron is a small-molecule drug. It absorbs reliably regardless of food intake and doesn't require the same dosing gymnastics. Take it with your morning coffee. Done.

The Phase 3 ACHIEVE-1 trial demonstrated approximately 14.7% body weight reduction at the highest dose (36mg daily) over 72 weeks. That's not quite injectable semaglutide territory (15–17%), and well below tirzepatide (20–22%), but the convenience trade-off is enormous. A daily pill that produces 35–45 lbs of weight loss in the average overweight man, with no injection, no compounding pharmacy uncertainty, and potentially standard insurance formulary coverage? That's going to move the market.

What This Means for Men Specifically

Beyond injection convenience, orforglipron opens several doors for men. First, it normalizes obesity treatment. Taking a daily pill feels like taking a statin or blood pressure medication — it removes the medical-procedure feeling that injections carry. For men who already take supplements, adding another pill to the morning routine is frictionless.

Second, orforglipron may have a smoother GI side effect profile than injectable GLP-1s. The dose titration is more gradual, and the daily dosing maintains steadier plasma levels without the peak-trough pattern of weekly injections. Men who've tried semaglutide and struggled with nausea or appetite suppression that's too aggressive on injection day may find orforglipron more tolerable.

Third — and this is speculative but worth noting — an oral GLP-1 with a clear path to insurance formulary coverage could dramatically reduce out-of-pocket costs compared to compounded injectables. That matters for the millions of men who can't justify $200–$400/month for weight loss medication but could manage a $30–$60/month copay.

CagriSema — The Most Powerful Weight Loss Drug Ever Tested

If orforglipron is the convenience play, CagriSema is the raw power play. By combining semaglutide (the GLP-1 agonist you know) with cagrilintide (an amylin analog that suppresses appetite through a completely different brain pathway), Novo Nordisk has created the most effective obesity medication ever tested in clinical trials.

The REDEFINE-2 trial results were staggering. Adults with obesity but without diabetes lost an average of 24.6% of their body weight over 68 weeks. To put that in concrete male terms: a 280-pound man losing 24.6% of his body weight reaches 211 lbs. That's not a modest improvement — that's a complete physical transformation, the kind that typically requires bariatric surgery.

The REDEFINE-1 trial in adults with type 2 diabetes showed 22.7% weight loss, which is remarkable given that diabetes typically makes weight loss harder. For men with T2D and obesity — a massive population — CagriSema could be the first medication that achieves surgery-level results pharmacologically.

The Amylin Angle for Men

Amylin is a hormone co-secreted with insulin by the pancreas. It slows gastric emptying, suppresses glucagon, and acts on the area postrema in the brainstem to produce satiety. Critically, the amylin pathway is distinct from the GLP-1 pathway, which means CagriSema is hitting appetite suppression from two completely independent neurochemical angles.

For men, this dual mechanism may be particularly relevant. Male eating patterns tend to be driven more by quantity and less by snacking — men are more likely to overeat at meals than between them. Amylin's effect on gastric emptying and meal-related satiety targets exactly this pattern, potentially making the appetite suppression feel less like "never hungry" and more like "satisfied with a normal portion."

The potential downside: with 24%+ weight loss, muscle preservation becomes critical. Novo Nordisk hasn't published male-specific body composition data from CagriSema trials yet, and the aggressive weight loss could amplify the lean mass loss concern that already exists with semaglutide alone. Men considering CagriSema (once available) should plan their resistance training and protein intake even more carefully than with current GLP-1 options — see our muscle preservation protocol.

Retatrutide — The Triple Agonist

Retatrutide is Eli Lilly's answer to CagriSema, and it might be even more interesting from a metabolic perspective. While tirzepatide activates GLP-1 and GIP receptors, retatrutide adds glucagon receptor agonism — a third pathway that brings unique metabolic benefits.

Glucagon is typically thought of as glucose-raising hormone that opposes insulin. But at the doses activated by retatrutide, glucagon receptor agonism does something remarkable: it increases energy expenditure (thermogenesis), accelerates liver fat clearance, and may promote more favorable body composition changes. The Phase 2 data showed 24.2% weight loss at the highest dose (12mg weekly) over 48 weeks — and the weight loss curves hadn't plateaued yet, suggesting even greater efficacy at 72 weeks.

Why Retatrutide Might Be the Best Option for Men

The glucagon pathway has several male-specific advantages worth highlighting:

Liver fat: Retatrutide showed dramatic reductions in liver fat — up to 85.6% reduction in hepatic steatosis in a MASLD sub-study. Non-alcoholic fatty liver disease (NAFLD/MASLD) affects approximately 30–40% of men and is a major driver of metabolic dysfunction. No other obesity medication has shown this level of liver fat clearance.

Energy expenditure: Glucagon receptor activation increases basal metabolic rate. For men, who already have higher baseline metabolic rates, this could mean more absolute calories burned during weight loss — potentially preserving the metabolic advantage that men have over women in weight loss trials.

Body composition: Early signals suggest the thermogenic effect of glucagon may preferentially mobilize fat while relatively sparing lean mass. This is preliminary and needs Phase 3 confirmation, but if true, retatrutide could partially address the muscle loss concern that haunts GLP-1 therapy in fitness-conscious men.

The catch: retatrutide is further from market than orforglipron or CagriSema. Phase 3 trials (TRIUMPH program) are ongoing, with results expected in 2027 and potential approval in late 2027 or 2028. This is not a "wait for it" drug — it's a "keep an eye on it while you use what's available" drug.

Survodutide — The Liver-Targeting Dual Agonist

Survodutide takes a different approach from retatrutide — it's a dual agonist (GLP-1 + glucagon) without the GIP component. The weight loss (~18.7% in Phase 2) falls between semaglutide and tirzepatide, but survodutide's real differentiator is its liver-targeting profile.

In the Phase 2 COURAGE-NASH trial, survodutide achieved MASH (metabolic dysfunction-associated steatohepatitis) resolution in 83% of participants at the highest dose — a rate that far exceeds any other pharmacological intervention. For the millions of men with fatty liver disease progressing toward cirrhosis, this is potentially transformative.

Men should pay particular attention to survodutide because male sex is an independent risk factor for MASH progression, and alcohol consumption — which is more prevalent among men — accelerates the disease. A weight loss medication that simultaneously treats MASH could prevent liver transplants and save lives.

Oral Tirzepatide — Eli Lilly's Convenience Play

Eli Lilly is developing an oral formulation of tirzepatide, attempting to bring the best-in-class weight loss of injectable tirzepatide (20–22%) to a pill. If successful, this would combine orforglipron's convenience with tirzepatide's superior efficacy.

This is early-stage and years from market. It's included here because it represents the ultimate end-state: a daily pill that produces 20%+ body weight loss. For now, men who want oral convenience should watch orforglipron, and men who want maximum weight loss should use injectable tirzepatide.

Pipeline Comparison: Every Drug Side by Side

Should You Wait? The Honest Assessment

This is the question men always ask when they see the pipeline: "Should I wait for something better?"

Consider the math. If you start compounded semaglutide today and lose 15% of your body weight over the next 12 months, you'll have already achieved the testosterone restoration, cardiovascular protection, and metabolic reset that matter. When orforglipron or CagriSema becomes available, you can switch if the newer option offers a meaningful advantage for your situation.

The men who benefit from pipeline drugs aren't the men who waited — they're the men who started treatment, lost significant weight, and then had the option to optimize further as new medications became available.

The only exception: if you refuse to inject and won't consider it under any circumstances, waiting 6–9 months for orforglipron may be reasonable. But even then, consider that oral semaglutide is available today as a no-injection alternative.

What to Start Today While You Watch the Pipeline

The best strategy: start effective treatment now, maintain awareness of the pipeline, and be ready to switch when better options become available. Here are the best current-day options for men.

For a comprehensive comparison of every GLP-1 provider, including pricing, medication options, and male-specific protocols, see our full 2026 provider rankings. And for the broader medication landscape beyond GLP-1s, check our complete weight loss medication guide for men.

The pipeline is exciting. But the best obesity medication is the one you're taking today — not the one you're waiting for. For detailed pricing on current options, visit GLP-1PriceList.com.